These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 769721)
41. A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder. Paterson R; Douglas C; Hallmayer J; Hagan M; Krupenia Z Aust N Z J Psychiatry; 1999 Aug; 33(4):494-502. PubMed ID: 10483843 [TBL] [Abstract][Full Text] [Related]
43. ADHD in girls: clinical comparability of a research sample. Sharp WS; Walter JM; Marsh WL; Ritchie GF; Hamburger SD; Castellanos FX J Am Acad Child Adolesc Psychiatry; 1999 Jan; 38(1):40-7. PubMed ID: 9893415 [TBL] [Abstract][Full Text] [Related]
44. Medication compliance in hyperactive children. Kauffman RE; Smith-Wright D; Reese CA; Simpson R; Jones F Pediatr Pharmacol (New York); 1981; 1(3):231-7. PubMed ID: 7346742 [TBL] [Abstract][Full Text] [Related]
45. A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder. Pelham WE; Aronoff HR; Midlam JK; Shapiro CJ; Gnagy EM; Chronis AM; Onyango AN; Forehand G; Nguyen A; Waxmonsky J Pediatrics; 1999 Apr; 103(4):e43. PubMed ID: 10103335 [TBL] [Abstract][Full Text] [Related]
46. Rate-dependent effects of d-amphetamine on locomotor activity in mice: possible relationship to paradoxical amphetamine sedation in minimal brain dysfunction. Glick SD; Milloy S Eur J Pharmacol; 1973 Nov; 24(2):266-8. PubMed ID: 4797286 [No Abstract] [Full Text] [Related]
47. Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention deficit/hyperactivity disorder. Castellanos FX; Elia J; Kruesi MJ; Marsh WL; Gulotta CS; Potter WZ; Ritchie GF; Hamburger SD; Rapoport JL Neuropsychopharmacology; 1996 Feb; 14(2):125-37. PubMed ID: 8822535 [TBL] [Abstract][Full Text] [Related]
48. The use of an N-of-1 randomised clinical trial in resolving therapeutic doubt. The case of a patient with an 'attention disorder'. Kamien M Aust Fam Physician; 1998 Jul; 27 Suppl 2():S103-5. PubMed ID: 9679365 [TBL] [Abstract][Full Text] [Related]
49. Placebo-controlled evaluation of amphetamine mixture-dextroamphetamine salts and amphetamine salts (Adderall): efficacy rate and side effects. Ahmann PA; Theye FW; Berg R; Linquist AJ; Van Erem AJ; Campbell LR Pediatrics; 2001 Jan; 107(1):E10. PubMed ID: 11134474 [TBL] [Abstract][Full Text] [Related]
50. SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results of a Randomized, Double-Blind Placebo-Controlled Study. Brams M; Childress AC; Greenbaum M; Yu M; Yan B; Jaffee M; Robertson B J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):19-28. PubMed ID: 28816509 [TBL] [Abstract][Full Text] [Related]
51. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456 [TBL] [Abstract][Full Text] [Related]
52. Stimulant medication withdrawal during long-term therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Nolan EE; Gadow KD; Sprafkin J Pediatrics; 1999 Apr; 103(4 Pt 1):730-7. PubMed ID: 10103294 [TBL] [Abstract][Full Text] [Related]
53. The use of lisdexamfetamine dimesylate for the treatment of ADHD. Childress AC; Sallee FR Expert Rev Neurother; 2012 Jan; 12(1):13-26. PubMed ID: 22243042 [TBL] [Abstract][Full Text] [Related]
54. Urinary MHPG excretion in minimal brain dysfunction and its modification by d-amphetamine. Shekim WO; Dekirmenjian H; Chapel JL Am J Psychiatry; 1979 May; 136(5):667-71. PubMed ID: 434244 [TBL] [Abstract][Full Text] [Related]
55. Single- and multiple-dose pharmacokinetics of an oral mixed amphetamine salts extended-release formulation in adults. Clausen SB; Read SC; Tulloch SJ CNS Spectr; 2005 Dec; 10(12 Suppl 20):6-15. PubMed ID: 16344836 [TBL] [Abstract][Full Text] [Related]
56. Platelet alpha 2-adrenergic receptor binding and the effects of d-amphetamine in boys with attention deficit hyperactivity disorder. Shekim WO; Bylund DB; Hodges K; Glaser R; Ray-Prenger C; Oetting G Neuropsychobiology; 1994; 29(3):120-4. PubMed ID: 8022532 [TBL] [Abstract][Full Text] [Related]
57. Pemoline (Cylert) for minimal brain dysfunction. Med Lett Drugs Ther; 1976 Jan; 18(2):5-6. PubMed ID: 1107790 [No Abstract] [Full Text] [Related]
58. The hyperactive child syndrome: peripheral sympathetic nervous system function and the effect of d-amphetamine. Mikkelsen E; Lake CR; Brown GL; Ziegler MG; Ebert MH Psychiatry Res; 1981 Apr; 4(2):157-69. PubMed ID: 6939007 [TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. Findling RL; Childress AC; Cutler AJ; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):395-405. PubMed ID: 21421179 [TBL] [Abstract][Full Text] [Related]
60. Effect of lisdexamfetamine dimesylate on parent-rated measures in children aged 6 to 12 years with attention-deficit/hyperactivity disorder: a secondary analysis. Lopez FA; Ginsberg LD; Arnold V Postgrad Med; 2008 Sep; 120(3):89-102. PubMed ID: 18824828 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]